#1
#1 out of 2
health1d ago
The Science Behind the Quest for a Non-Peptide Oral Weight Loss Drug A
- The FDA approved orforglipron, the first non-peptide GLP-1 agonist, marketed as Foundayo.
- Orforglipron is a small molecule designed to activate the GLP-1 receptor, unlike injectable peptide therapies.
- Researchers used Cryo-EM to map the GLP-1 receptor’s binding pocket, guiding molecule design.
- AI-assisted retrosynthesis helped chemists find scalable routes to manufacture orforglipron.
- Orforglipron offers a more convenient and cheaper alternative to injectable GLP-1 therapies.
- The article notes Wegovy’s injectable form and the new oral option as a potential shift in obesity treatment.
- The discovery traced the receptor to a 463-amino-acid protein that GLP-1 binds.
- Foundayo's development blended human research with AI tools to achieve viability.
- The article cites a 72-week trial showing meaningful weight reduction with no significant side effects.
Vote 0